Evidence map›Paper›PMID 32818842›Full record

ArticleNeoplasia (New York, N.Y.)2020

Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma.

Christopher S Koivisto, Melodie Parrish, Santosh B Bonala, Soo Ngoi, Adrian Torres, James Gallagher, Rebekah Sanchez-Hodge, Victor Zeinner, Georges J Nahhas, Bei Liu and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neoplasia (New York, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Androgens in endometrial carcinoma: the killer or helper?Journal of endocrinological investigation · 2023
    Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Christopher S KoivistoDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA. Electronic address: koivisto@muscu.edu.
Melodie ParrishDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA. Electronic address: parrism@musc.edu.
Santosh B BonalaDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA. Electronic address: bonala@musc.edu.
Soo NgoiDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA. Electronic address: ngoi@musc.edu.
Adrian TorresDepartment of Molecular Genetics, The Ohio State University, Columbus, OH, USA. Electronic address: adrian.torres@osumc.edu.
James GallagherDepartment of Molecular Genetics, The Ohio State University, Columbus, OH, USA. Electronic address: james.gallagher@osumc.edu.
Rebekah Sanchez-HodgeDepartment of Molecular Genetics, The Ohio State University, Columbus, OH, USA; Department of Veterinary Preventive Medicine, The Ohio State University, Columbus, OH, USA.
Victor ZeinnerDepartment of Molecular Genetics, The Ohio State University, Columbus, OH, USA.
Georges J NahhasDepartment of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA. Electronic address: elnahas@musc.edu.
Bei LiuDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA. Electronic address: liube@musc.edu.
David E CohnDivision of Gynecologic Oncology, College of Medicine, The Ohio State University, Columbus, OH, USA. Electronic address: david.cohn@osumc.edu.
Floor J BackesDivision of Gynecologic Oncology, College of Medicine, The Ohio State University, Columbus, OH, USA. Electronic address: floor.backes@osumc.edu.
Paul J GoodfellowDepartment of Obstetrics and Gynecology, College of Medicine, The Ohio State University, Columbus, OH, USA. Electronic address: paul.goodfellow@osumc.edu.
Helen M ChamberlinDepartment of Molecular Genetics, The Ohio State University, Columbus, OH, USA. Electronic address: chamberlin.27@osu.edu.
Gustavo LeoneDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA. Electronic address: leoneg@musc.edu.
The Ohio State University · USMUSC Hollings Cancer Center · USMedical University of South Carolina · US

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RAYMOND N. DUBOIS · 2009 to 2026
$42.7M
Proteomics CoreP30DK123704 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DON C. ROCKEY · 2020 to 2026
$8.8M
Tumor Suppressor Roles of E2F7 & E2F8 in Hepatocellular Carcinoma (HCC)R01CA121275 · NCI · OHIO STATE UNIVERSITY · PI LEONE, GUSTAVO WALTER · 2008 to 2018
$3.1M
NCI NIH HHS P30 CA138313NCI NIH HHS R01 CA121275NIDDK NIH HHS P30 DK123704
6 · The paper itself

Abstract

Androgen Receptor (AR) signaling is a critical driver of hormone-dependent prostate cancer and has also been proposed to have biological activity in female hormone-dependent cancers, including type I endometrial carcinoma (EMC). In this study, we evaluated the preclinical efficacy of a third-generation AR antagonist, enzalutamide, in a genetic mouse model of EMC, Sprr2f-Cre;Pten

Indexed as

ApoptosisDisease Models, AnimalDrug Resistance, NeoplasmAnimalsBenzamidesCell ProliferationCornified Envelope Proline-Rich ProteinsEndometrial NeoplasmsFemaleMaleMiceMice, KnockoutNitrilesPhenylthiohydantoinPTEN PhosphohydrolaseSignal TransductionBenzamidesCornified Envelope Proline-Rich ProteinsenzalutamideNitrilesPhenylthiohydantoinPTEN PhosphohydrolasePten protein, mouseSprr2f protein, mouseAndrogen receptor antagonistEndometrial carcinomaEnzalutamideMouse model of endometrial cancerPreclinical drug evaluationPTEN

Identifiers

PMID32818842
PMCPMC7452078
OpenAlexW3075177525

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.